Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol
- 14 September 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (11), 1456-1462
- https://doi.org/10.1161/01.cir.0000141573.44737.5a
Abstract
Background— An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol. Methods and Results— A total of 960 patients with essential hypertension and LV hypertrophy (LVH) on screening ECG were enrolled at centers in 7 countries and studied by echocardiography at baseline and after 1, 2, 3, 4, and 5 years’ randomized therapy. Clinical examination and blinded readings of echocardiograms in 457 losartan-treated and 459 atenolol-treated participants with ≥1 follow-up measurement of LV mass index (LVMI) were used in an intention-to-treat analysis. Losartan-based therapy induced greater reduction in LVMI from baseline to the last available study than atenolol with adjustment for baseline LVMI and blood pressure and in-treatment pressure (−21.7±21.8 versus −17.7±19.6 g/m2; P=0.021). Greater LVMI reduction with losartan was observed in women and men, participants >65 or Conclusions— Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment. Thus, angiotensin receptor antagonism by losartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.Keywords
This publication has 23 references indexed in Scilit:
- Impact of Different Partition Values on Prevalences of Left Ventricular Hypertrophy and Concentric Geometry in a Large Hypertensive PopulationHypertension, 2000
- Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE studyJournal of the American College of Cardiology, 1999
- Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)Nephrology Dialysis Transplantation, 1998
- Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial)The American Journal of Cardiology, 1996
- Association of change in left ventricular mass with prognosis during long-term antihypertensive treatmentJournal Of Hypertension, 1995
- Electrocardiographic identification of increased left ventricular mass by simple voltage-duration productsJournal of the American College of Cardiology, 1995
- Association of carotid atherosclerosis and left ventricular hypertrophyJournal of the American College of Cardiology, 1995
- Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertensionJournal Of Hypertension, 1993
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986